Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate.

[1]  C. Mingora,et al.  A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus. , 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[2]  B. Collins,et al.  Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[3]  J. Beekman,et al.  Breast development in a 7 year old girl with CF treated with ivacaftor: An indication for personalized dosing? , 2021, Journal of Cystic Fibrosis.

[4]  S. Verbanck,et al.  A case of self-limited drug induced liver injury under treatment with elexacaftor/tezacaftor/ivacaftor: When it is worth taking the risk. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[5]  R. Kuhn,et al.  CFTR modulator drug desensitization: Preserving the hope of long term improvement , 2021, Pediatric pulmonology.

[6]  D. Kay,et al.  Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[7]  B. Quon,et al.  Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review , 2020, Journal of clinical medicine.

[8]  E. Schneider-Futschik,et al.  Multiple Reaction Monitoring Mass Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in Cystic Fibrosis: A High-Throughput Method. , 2020, ACS pharmacology & translational science.

[9]  J. Taylor-Cousar.  CFTR Modulators: Impact on Fertility, Pregnancy, and Lactation in Women with Cystic Fibrosis , 2020, Journal of clinical medicine.

[10]  R. Dezube,et al.  Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis. , 2020, Journal of Cystic Fibrosis.

[11]  S. Rotolo,et al.  Testicular pain following initiation of elexacaftor/tezacaftor/ivacaftor in males with cystic fibrosis. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[12]  E. Acosta,et al.  Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[13]  M. Duno,et al.  Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients , 2017, Pediatric pulmonology.

[14]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[15]  G. Jürgens,et al.  Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[16]  E. Acosta,et al.  A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma. , 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[17]  S. Noel,et al.  Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. , 2012, Clinical biochemistry.

[18]  J. Treluyer,et al.  Drug Disposition in Cystic Fibrosis , 1998, Clinical pharmacokinetics.

[19]  W. Jusko,et al.  Altered prednisolone pharmacokinetics in patients with cystic fibrosis. , 1992, The Journal of pediatrics.

[20]  R. Parsons,et al.  Absorption of two antibacterial drugs, cephalexin and co-trimoxazole, in malabsorption syndromes. , 1975, Journal of Antimicrobial Chemotherapy.